Abstract 498P
Background
Frailty is of importance for older lung cancer patients, but the remaining lifetime is still not estimated for frailty but solely relied on cancer stage or cell type. In this study, we aimed to estimate survival and life expectancy of older non-small cell lung cancer patients (NSCLC) by frailty status, using electronic-health records.
Methods
We retrospectively analyzed 4260 patients aged between 65 and 95 who were newly diagnosed with NSCLC in 2007-2018 in National Cancer Center, Korea and followed up until December 2020. Frailty was measured by laboratory tests before initial treatment (FI-Lab), then classified into non-frail (score <0.25) and frail groups (score>0.25). Kaplan-Meier curves and log-rank test were used to compare survival probabilities by frailty. Cox proportional hazard model were used to estimate effect of frailty on all-cause mortality, adjusted for age, sex and SEER stage. We also estimate average life expectancy by frailty for all patients and stratified by SEER stage.
Results
There were 1063 (25%) patients identified as being frail. Frail patients had a significantly poorer survival than the non-frail in total population, and in SEER stage groups. Overall, frailty is significantly associated with all-cause mortality (aHR: 1.65, 95% CI: 1.52-1.78). Average life expectancies of frail older patients were 7.75 (95% CI 6.48-9.27) years for localized stage, 3.55 (95% CI 3.05-4.08) years for regional stage and 0.89 (95% CI 0.78-1.02) years for distant stage. While these figures for non-frail patients diagnosed in same cancer stage were 10.05 (95% CI 9.49-11.38), 4.99 (95% CI 4.67-5.32), 1.94 (95%CI 1.82-2.06) respectively.
Conclusions
Survival and life expectancy of older NSCLC patients vary by frailty status. In clinical settings, frailty can be simply assessed by laboratory tests to provide more precise estimates of remaining life-year and help oncologists to better plan for treatment decision and follow-up.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Cancer Center Grant (No. NCC-2210880-2, NCC-2310450-1). In addition, one of the authors, Minh Thao Tu was supported by the “International Cooperation & Education Program” (NCCRI·NCCI 52210-52211, 2023)” of National Cancer Center, Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract